Skip to main content
Therapeutic Advances in Psychopharmacology logoLink to Therapeutic Advances in Psychopharmacology
. 2026 Feb 12;16:20451253251406059. doi: 10.1177/20451253251406059

Sex, drugs, and arousal—two randomized trials on the effects of ketamine on sexual arousal and calcarine gyrus activity

Manfred Klöbl 1,2, Thomas Liebe 3, Gregor Dörl 4,5, Peter Stöhrmann 6,7, Clemens Schmidt 8,9, Elisa Briem 10,11, Christian Milz 12,13, Gabriel Schlosser 14,15, Maximilian Kathofer 16, David Gomola 17,18, Godber Mathis Godbersen 19,20, Julia Sophia Crone 21, Rupert Lanzenberger 22,23,, Marie Spies 24,25
PMCID: PMC12901892  PMID: 41693798

Abstract

Background:

Ketamine, a well-established antidepressant and dissociative anesthetic, is also used recreationally in the club and chemsex scene. Survey and qualitative data suggest that while ketamine facilitates chemsex encounters, it diminishes the intensity of the sexual experience.

Objectives:

To investigate this phenomenon from a neuroscientific perspective while considering ketamine’s sex-specific effects.

Design:

Two randomized, placebo-controlled crossover studies using intranasal S-ketamine (double-blinded) or intravenous racemic ketamine (single-blinded).

Methods:

Subjective sexual arousal in response to a newly compiled set of erotic stimuli was assessed following subacute S-ketamine and late racemic ketamine administration across two studies. Overall, 67 healthy volunteers (26 females) participated in the studies. Functional magnetic resonance imaging (fMRI) was performed during sexual arousal assessment under late racemic ketamine exposure, with both studies also incorporating resting-state fMRI assessments.

Results:

Subacute S-ketamine reduced sexual arousal to heterosexual stimuli in women (β = −0.21, CI95 = (−0.36, −0.06)) and, to a lesser extent, to lesbian stimuli in men (β = −0.16, CI95 = (0.003, −0.33)). It also diminished sexual aversion to gay stimuli in both sexes (β ⩾ 0.18, CI95 ⩾ (0.03, 0.32)). Conversely, late racemic ketamine decreased sexual arousal to heterosexual stimuli in men (β = −0.17, CI95 = (−0.31, −0.02)) while exacerbating sexual aversion to gay stimuli in women (β = −0.24, CI95=(−0.36,−0.12)). Furthermore, late ketamine administration resulted in reduced calcarine gyrus activation in men compared to women, independent of sexual arousal (β ⩽ −0.23, CI95 ⩽ (−0.52, 0.05)). This finding was confirmed for resting activity under subacute ketamine (β = −0.18, CI95 = (−0.32, −0.04)).

Conclusion:

Our results align with reports of diminished sexual arousal under ketamine, while the reduced sexual aversion may play a role in facilitating chemsex. The heightened sexual aversion in women and the distinct calcarine gyrus activity modulation may relate to previously documented sex-dependent ketamine effects on stress resilience and psychosis-like symptoms.

Trial registration:

Both studies were registered at clinicaltrials.gov: NCT05320120 (2022-04-08), NCT05320107 (2022-04-08).

Keywords: functional magnetic resonance imaging, ketamine, resting-state, sex differences, sexual arousal

Introduction

Initially developed as an anesthetic, ketamine has evolved into a versatile drug in both clinical practice and research. 1 Beyond its medical applications, ketamine is highly utilized in the chemsex24 and club scene.57 In particular, among men who have sex with men, drugs are consumed to alter or intensify the sexual and emotional experience. 3 However, survey data indicate that ketamine is more frequently reported to worsen sexual experiences than to enhance them 8 and anecdotal evidence suggests its use to facilitate passive anal intercourse. 9 Still, the underlying effects of ketamine on sexual arousal remain unexplored from both neural and behavioral perspectives.

Even at subanesthetic doses, Ketamine induces changes in neural activity and functional connectivity, as demonstrated through functional magnetic resonance imaging (fMRI) and other modalities. These effects are particularly pronounced in visual regions and have been linked to reduced attention and vigilance, as well as psychotomimetic effects.1016 The primary visual region anatomically corresponds to the calcarine cortex, which contains a representation of the retinotopic map. 17 Beyond its role in the low-level processing of, for example, saccades and spatial attention,18,19 the calcarine cortex is also activated by mental imagery. 20 Studies have shown that ketamine reduces functional connectivity between visual brain regions, 13 reduces visual cortex activation during smooth pursuit eye movements, 14 and reduces cerebral blood flow in the primary visual cortex of individuals with schizophrenia. 16

Notably, a prohedonic component has been proposed in connection with ketamine’s antidepressant properties,21,22 suggesting its potential to enhance reward-seeking behavior. Preclinical and clinical evidence further indicate that ketamine’s rewarding effects are context-dependent, with higher doses more frequently consumed in unfamiliar environments (e.g., clubs and parties). 23 These findings could provide starting points for a mechanistic and behavioral understanding of recreational ketamine use in stimulating, pleasure-oriented environments, such as the chemsex scene.

When examining ketamine’s effects on sexual arousal, it is crucial to consider sex differences for both sexual arousal and ketamine’s effects. Furthermore, sexual arousal has been shown to be influenced by gender identity, in addition to the type of stimuli and the method of assessment. 24 Animal studies have revealed potential sex differences in depression-related behavioral responses to ketamine,2528 while human studies have linked sex differences in ketamine’s antidepressant effects to sex hormones. 29 The predominance of men who have sex with men in the chemsex scene30,31 underscores the importance of sex and gender as key factors, though studies from France and Italy highlight significant chemsex participation among women as well.8,32

In this context, we hypothesized that ketamine’s effects on sexual arousal and aversion, as well as brain activation, could vary in two ways: If ketamine exerts prohedonic effects also in healthy individuals, we would expect increased sexual arousal to stimuli that were rated as arousing under placebo. Conversely, decreased sexual arousal would corroborate reports of worsened sexual experiences under ketamine. Given known differences in sexual preferences, these effects would necessarily be modulated by the sex of the participants and the sexual orientation of the stimuli.24,33 These hypotheses were tested in healthy volunteers across two studies examining subacute and late ketamine effects (relative to the peak of the subjective high) using self-reported sexual arousal and fMRI data collected at rest and during a sexual arousal task. Since we only enrolled healthy individuals, benefits and harms were limited to the expense allowance and potential drug side effects, respectively.

Methods and materials

We investigated the effects of ketamine on sexual arousal in two studies using a newly compiled set of erotic stimuli. Participants were recruited through flyers posted on designated message boards at the General Hospital of Vienna and throughout the city. Inclusion criteria for both studies encompassed age 18–55 years, general physical and mental health based on medical history, physical examination, and Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders (DSM; SCID), right-handedness to ensure equal lateralization, no past or present substance abuse, and no lifetime use of ketamine. Studies 1 and 2 used the SCID for DSM-IV 34 and DSM-5, 35 respectively. Both versions represent standards in psychiatric diagnostics and have been validated extensively (e.g., Osório et al., 36 Gorgens et al. 37 ). Participants were excluded if they had a current or past history of psychiatric or neurological disorders, current illnesses requiring treatment, current or past substance abuse, were pregnant or breastfeeding, or had a contraindication to ketamine or MRI investigations. In addition, Study 2 did not permit any lifetime use of ketamine. After passing the initial screening and providing written informed consent, participants were enrolled by the study physician or medical students under supervision. Dropouts based on overall study objectives were replaced, and recruitment ended after the intended sample sizes were achieved.

Randomization, as described below, was performed by a team member not further involved in the studies. The randomization lists were stored on a password-protected network drive and were only sent to the pharmacy of the Medical University of Vienna for drug preparation upon participant enrollment.

All study procedures were performed at the Medical University of Vienna. fMRI data were acquired using a Siemens Prisma 3T scanner at the university’s High-field Magnetic Resonance Center. The analyses in this manuscript were exploratory, and the measures were not registered as primary or secondary outcomes. Descriptive statistics are provided as median ± interquartile range. The reporting of this study conforms to the CONSORT guidelines. 38 For details on participant inclusion and exclusion, see the accompanying CONSORT flow diagrams.

Compiling the novel stimulation material

Following recent recommendations advocating for women to select visual erotic stimuli in sexual arousal research, 39 we developed a novel set of stimulation materials. Research staff and students involved in the studies were tasked with selecting heterosexual, female (lesbian), and male (gay) homosexual images from a public database of pornographic movie stills. Alternative sources were permitted if no suitable images were identified. To ensure anonymity, participants labeled the images with their self-identified gender (male, female), sexual orientation (heterosexual, bisexual, homosexual), and a unique random code generated once per individual. This process maintained confidentiality while indicating which images were chosen by the same person.

In addition to meeting image quality standards, the selected stimuli had to fulfill the following criteria: depict exactly two individuals engaged in intercourse, exclude fetishes to ensure broad appeal, and elicit subjective sexual arousal when the scene’s orientation aligned with that of the selector However, we must note that, apart from these criteria, no validation and reliability assessments have been conducted with the stimuli to date. From the compiled images, 36 of each orientation (108 total) were chosen, prioritizing those selected by individuals whose self-reported gender and orientation matched the depicted scene (e.g., lesbian stimuli preferred images chosen by lesbian or bisexual women). If fewer than 36 images met these criteria, a balanced selection was made, considering all other variables (i.e., selector identity, gender, and orientation).

Study 1—Reported sexual arousal after intranasal S-ketamine

Study 1 investigated the subacute ketamine effects on subjective sexual and general arousal as well as on resting fMRI brain activity.

Study procedure and design

The sample size was estimated based on a calculated effect size of f = 0.25 (r = 0.60, 1 – β = 0.80).40,41 Reliability was assumed to be r = 0.54. 42 A within-subject analysis of variance (ANOVA) and two covariates yielded a sample size of N = 33. Participants were recruited from the beginning of June 2022 to the end of April 2023 and followed up until mid-June 2023. The first subject was enrolled on June 9, 2022. Thirty participants (24.0 ± 2.0 years, 15 females) received 56 mg intranasal S-ketamine (Spravato) or placebo (saline) in a randomized, double-blind, crossover fashion with 14 ± 14.5 days between sessions. This drug application scheme was chosen to maximize comparability with the clinical practice for the antidepressant use of S-ketamine. The order of conditions was block-randomized with a block size of six. Blinding was achieved by using identical nasal spray bottles and covering the labels with opaque adhesive tape.

Sexual and general arousal task

Participants rated all 108 images from our stimulus set, presented in random order on a laptop, using visual analog scales in the rooms of the Department of Psychiatry and Psychotherapy of the Medical University of Vienna. Sexual arousal ratings ranged from “strongly turning off” to “strongly turning on,” whereas general arousal ratings ranged from “very calming” to “very exciting.” The task commenced 146 ± 14 min (approximately 2.5 h) after drug administration (the acute phase was reserved for MRI scans presented elsewhere).

fMRI acquisition, processing, and modeling

Resting-state fMRI data were acquired 45 ± 4 min after drug administration over an 8-minute period using the following parameters: echo time/repetition time (TE/TR) = 30/1114 ms, 2-mm isotropic resolution, a field of view of 208 × 208 × 144 mm, multiband factor 4, generalized autocalibrating partial parallel acquisition (GRAPPA) factor 2, and a bandwidth of 2290 Hz/Px.

Unless otherwise specified, preprocessing was conducted in Statistical Parametric Mapping 12 (SPM12). The steps included physiological noise modeling and regression, 43 slice-wise motion correction, 44 wavelet despiking, 45 slice-timing correction, distortion correction, 46 realignment across sessions, and normalization (preserving the original voxel dimensions) 47 via a T1-weighted scan. These steps were followed by gray matter masking and Gaussian smoothing with a kernel size equivalent to three times the voxel dimension. Nuisance regression anatomical CompCor 48 and bandpass filtering 49 (0.01–0.10 Hz). Surrogates of resting brain activity were computed as percent amplitude of fluctuation (PerAF 50 ) from smoothed data and regional homogeneity (ReHo 51 ) from unsmoothed data.

Statistical analysis

Bayesian inference on the level of single-image ratings was conducted using mixed effects models in R using Integrated Nested Laplace Approximation (INLA 52 ). This allowed for the inclusion of partially available data without special handling of missing values. Model selection via the Watanabe–Akaike Information Criterion resulted in the following specification:

SA~drugorientsextime+age+habit+order+GAsexorient+(1|subject)+(1|stim)

Sexual arousal (SA) scores were scaled to the interval (0, 1) and modeled with a beta distribution using a logit link function. Given that chromosomal sex influences ketamine’s effects 29 and reported SA, 24 the model includes an interaction between drug, participant sex, and stimulus orientation, adjusted for the logarithm of the time since drug application. Additional covariates comprised participant age, potential habituation effects from repeated measurements, order of drug application, and Fisher-z-transformed general arousal (GA) for each stimulus orientation and participant sex. Crossed random effects were incorporated for subjects and stimuli.

INLA reports effects with 95% credible intervals (CIs), where intervals not overlapping zero serve as a rough equivalent to p-values < 0.05. This Bayesian multilevel approach further mitigates concerns regarding multiple comparisons, eliminating the need for additional corrections. 53

Study 2—Reported and neural sexual arousal after intravenous racemic ketamine

Study 2 complemented the investigation of subacute ketamine effects in Study 1 by brain activation and subjective responses collected via an fMRI SA task and resting fMRI brain activity during late ketamine effects.

Study procedure and design

The target sample size was chosen as typical for pharmaco-fMRI studies. Participants were recruited from the beginning of June 2022 until mid-June 2023 and followed up until the end of November 2023. The first subject was enrolled on August 9, 2022. Thirty-seven participants (23.7 ± 2.2 years, 21 females) received an intravenous dose of 0.5 mg/kg racemic ketamine diluted with saline or saline alone (placebo) over 40 min in a randomized, single-blind, crossover fashion. The infused solutions were indistinguishable to the participants. The sessions were 19 ± 28 days apart. This drug application scheme was chosen to maximize comparability with the majority of the currently published ketamine research in healthy individuals. The order of conditions was block-randomized with a block size of 8. To account for variations in sexual orientation, they completed the Klein Sexual Orientation Grid (KSOG) on a tablet. The KSOG is widely used in sex research and assesses past, present, and ideal sexuality. For a reprint of the publication introducing the KSOG, see Klein. 54 For a confirmatory factor analysis highlighting some limitations of the questionnaire, see Cramer et al. 55

fMRI sexual arousal task

While undergoing MRI scanning, participants viewed 54 images from our stimulus set in random order and rated their SA on a four-point Likert scale (strongly turning on, turning on, turning off, strongly turning off 24 ) using an MR-compatible input device. Images were presented in 18 blocks, each containing 3 images of the same sexual orientation. Each stimulus was displayed for 7 s with baseline periods of 21 s between blocks. The task commenced 325 ± 12 min (approximately 5.5 h) after drug application.

fMRI acquisition, processing, and modeling

fMRI data of the SA task were acquired using the following parameters: TE/TR = 30/1600 ms, 3 mm isotropic resolution, field of view = 210 × 210 × 144 mm, multiband factor = 2, bandwidth = 1830 Hz/Px. Resting-state fMRI data were collected 249 ± 3 min (approximately 4 h) after drug administration for 10 min, with TR = 800 ms, multiband factor = 4, pixel bandwidth = 2040 Hz/Px, and otherwise identical parameters.

Preprocessing and resting-state procedures were performed as in Study 1. For the SA task, session-wise first-level models in SPM12 were constructed with one regressor per stimulus condition (heterosexual, lesbian, and gay), anatomical CompCor regressors, no high-pass filtering, and the “FAST” autoregression model. 56

Statistical analysis—Responses

Subjective ratings of SA were again modeled using INLA with a beta distribution and a logit link function. Responses were scaled to the interval (0.1, 0.9) following the quantification suggested in Safron et al. 57 (e.g., “strongly turning on” corresponds to the interval (0.8, 1.0)). The model was similar to that in Study 1, but was adjusted for the sex-specific first principal components derived from the sexual attraction, behavior, and fantasy items of the KSOG instead of GA. This adjustment accounted for variability in the responses for each orientation of the stimuli due to the sexual orientation of the participants. The final model, after model selection, was specified as:

SA~drugorientsextime+age+habit+order+(KSOGf+KSOGm)orient+(1|subject)+(1|image)

Statistical analysis—fMRI activation during sexual arousal task

Based on our previous fMRI investigation of SA, 24 the ventral striatum was first examined and did not reveal reliable effects of any predictor. Therefore, we performed a whole-brain group-level analysis using the Sandwich Estimator (SwE) toolbox version 2.2.2. 58 The design matrix was modeled as:

activation~drugorientsex+age+habit+order+time+(KSOGf+KSOGm)orient

SwE employs marginal models to account for repeated measures without random effects. “Type C2” small sample adjustment and “approx. II” degrees of freedom estimation were used, which are ideal for complete datasets. Cluster-level correction was achieved using AFNI’s 3dFWHMx followed by 3dClustSim with median autocorrelation parameters, and multiplicity was controlled with the Šidak method. The median activation from significant clusters was then extracted and further analyzed using INLA with the model:

activation~drugorientsex+age+habit+order+time+(KSOGf+KSOGm)orient+(1|subject)

Statistical analysis—Resting activity

Because the fMRI SA task revealed ketamine- and sex-related effects independent of stimulus orientation, we additionally examined the resting activity of the affected region in both studies for the generalizability of the finding. The following model was employed:

activity~drugsex+age+habit+order+time+(1|subject)

PerAF was modeled using a gamma distribution with a log link, while ReHo was modeled using a beta distribution with a logit link, in accordance with their natural distributions.

Positionality statement

The studies presented in this manuscript were conducted by researchers with diverse disciplinary and personal backgrounds to examine the effects of ketamine on subjective SA in healthy individuals. A central aspect of our hypothesis was the use of ketamine in the context of chemsex, which prompted investigation of its potential influence on SA. Our intention is to contribute positively to the scientific understanding of sexuality and the effects of ketamine rather than to pathologize recreational drug use, sexual preferences, or identities. In designing the task, we sought to compile a diverse and inclusive set of erotic stimuli, while recognizing that complete representation is not achievable, particularly within the constraints of a controlled study. We acknowledge that sexuality is a sensitive and multifaceted phenomenon, and our design captures only a limited aspect of its complexity. The development of novel stimulus material was also motivated by the reliance on outdated erotic stimuli in our earlier research. While our previous studies often revealed strong effects of ketamine in healthy individuals, our goal here is to present findings objectively, with a nuanced and differentiated discussion. Despite our efforts, limitations regarding inclusivity, diversity, and the scope of a visual task remain, and we therefore present our results with caution while encouraging future research that advances sensitivity and inclusivity in this field.

Results

Table 1 provides an overview of the demographics of the participants per study. Ketamine-related effects on SA are summarized in Table 2 for the model with female sex, heterosexual stimuli, and placebo as reference conditions and depicted in Figure 1. The full model and models with different reference conditions are detailed in the Supplemental File. Results for the SA task activation and resting activity are presented in Tables 3 and 4 and visualized in Figure 2.

Table 1.

Study demographics.

Value Study 1 Study 2
N (female) 30 (15) 37 (21)
Age (median ± IQR years) 24.0 ± 2.0 23.7 ± 2.2

Table 2.

Ketamine-related effects on reported sexual arousal and calcarine activation with 95%CI.

Effect Study 1:
Subacute S-ketamine
Study 2:
Late racemic ketamine
Reported sexual arousal Reported sexual arousal Calcarine gyrus activation
Estimate 95% CI Estimate 95% CI Estimate 95% CI
Ketamine 0.21 [0.36, −0.06] −0.05 [−0.16, 0.07] 0.09 [−0.10, 0.28]
Ketamine × lesbian 0.31 [0.10, 0.52] 0.04 [−0.11, 0.20] −0.09 [−0.36, 0.18]
Ketamine × gay 0.38 [0.18, 0.59] 0.19 [0.35, −0.03] 0.04 [−0.23, 0.31]
Ketamine × male 0.18 [−0.05, 0.40] −0.12 [−0.30, −0.06] 0.41 [0.69, −0.12]
Ketamine × lesbian × male 0.44 [0.75, −0.14] 0.06 [−0.19, 0.31] 0.18 [−0.23, 0.58]
Ketamine × gay × male −0.10 [−0.40, 0.20] 0.33 [0.07, 0.59] 0.03 [−0.37, 0.43]

Female subject sex, heterosexual stimuli, and the placebo condition were used as reference categories. Effects with 95% CIs not covering 0 are highlighted in bold.

CI, credible intervals.

Figure 1.

Figure 1.

Fitted reported sexual arousal per subject and trial. The values have been adjusted for the model covariates.

Table 3.

Significant whole-brain results.

Contrast Test Cluster size [voxel] p-Value Corrected p-Value Peak coordinates
Subject sex × stimulus orientation X 2 94 (+30) 0.0090 0.0355 15/−88/−4 (−12/−103/−7)
(male–female) × (hetero–gay) z 220 0.0005 0.0035 18/−94/−4
(male–female) × (lesbian–gay) z 305 <1e-5 0.0003 −12/−103/−7

In the X² test, the otherwise connected cluster was split into two; the smaller part is presented in parentheses. The p-value refers to the larger part only. X²-test corrected for four interaction effects. z-Tests additionally corrected for three pairwise comparisons.

Table 4.

Ketamine-related effects on calcarine gyrus resting activity with 95% CIs.

Effect Study 1:
Subacute S-ketamine
Study 2:
Late racemic ketamine
PerAF ReHo PerAF ReHo
Estimate 95% CI Estimate 95% CI Estimate 95% CI Estimate 95% CI
ketamine 0.09 [−0.02, 0.19] 0.02 [−0.22, 0.26] −0.04 [−0.14, 0.7] −0.01 [−0.18, 0.16]
ketamine × male −0.18 [−0.32, −0.04] −0.18 [−0.51, 0.16] −0.05 [−0.21, 0.10] 0.02 [−0.23, 0.26]

CIs, credible intervals; PerAF, percent amplitude of fluctuation; ReHo, regional homogeneity. Effects with 95% CIs not covering 0 are highlighted in bold.

Figure 2.

Figure 2.

Fitted task activation and resting activity per subject. The values have been adjusted for the model covariates. The rendering shows the significantly affected cluster in the calcarine gyrus.

Study 1—Reported sexual arousal after intranasal S-ketamine

No response data had to be excluded. In women, ketamine decreased reported SA to heterosexual stimuli (β = −0.21, CI95 = (−0.36, −0.06)) while reducing aversion to gay stimuli (β = 0.18, CI95 = (0.03, 0.32)). In addition, ketamine elevated women’s reported SA for lesbian stimuli, but only in comparison to heterosexual stimuli (β = 0.31, CI95 = (0.10, 0.52)). In men, ketamine reduced aversion to gay stimuli (β = 0.25, CI95 = (0.09, 0.41)) but slightly decreased reported SA for lesbian stimuli (β = −0.16, CI95 = (0.003, −0.33)). This reduction in men’s arousal for lesbian stimuli was particularly pronounced when compared to women’s responses (β = −0.27, CI95 = (−0.48, −0.04)). Notably, strong correlations were observed between sexual and GA, with a marked increase in GA for men’s ratings of gay stimuli (see Supplemental File). Overall, subacute S-ketamine effects were associated with diminished SA and aversion.

Study 2—Reported sexual arousal after intravenous racemic ketamine

The response data of one participant were excluded due to a potential individual bias, as nearly all stimuli were rated as “strongly dislike.” In addition, responses from two measurements were not recorded due to hardware errors. Consequently, the behavioral analysis included complete data from 33 participants and two single runs. For the fMRI analysis, data from two participants were excluded due to severe motion artifacts, leaving 35 datasets.

On average, female participants reported to be “mostly attracted to men” and identified as “mostly heterosexual.” Average reports for male participants showed that they were “mostly/only attracted to women” and identified as “heterosexual only.” See Supplemental File for details on the KSOG variables.

In women, compared to placebo, ketamine further increased aversion to gay stimuli (β = −0.24, CI95 = (−0.36, −0.12)), an effect particularly pronounced when compared to men’s responses (β = −0.21, CI95 = (−0.41, −0.01)). In men, ketamine decreased reported SA for heterosexual stimuli (β = −0.17, CI95 = (−0.31, −0.02)).

Ketamine effects on task activation and resting brain activity

No significant ketamine-related effects on whole-brain activation during the SA task were observed. However, a participant sex by stimulus orientation interaction was identified in the visual cortex (p = 0.0355; see Supplemental File for baseline activations). The affected cluster primarily encompassed the calcarine gyrus, extending into the lingual and lateral occipital gyri. Detailed analysis revealed that ketamine reduced activation in this cluster in men compared to women across all stimulus conditions, with a less pronounced effect for lesbian stimuli (hetero: β = −0.41, CI95 = (−0.69, −0.12), lesbian: β = −0.23, CI95 = (−0.52, 0.05), gay: β = −0.38, CI95 = (−0.67, −0.10); see also Supplemental File). At the whole-brain level, this effect was evident only at relaxed thresholds but extended considerably along the lingual gyrus, reaching the calcarine, hippocampal, and parahippocampal gyri (see Supplemental File).

In the calcarine gyrus cluster, resting activity estimated via PerAF in Study 1 showed the same effect, that is, reduced activity in men compared to women following ketamine administration (β = −0.18, CI95 = (−0.32, −0.04)). This effect was much less reliable for ReHo (β = −0.18, CI95 = (−0.51, 0.16)) and was not detectable in Study 2 (Table 4).

Discussion

In the current work, we examined the effects of ketamine versus placebo on SA across two studies utilizing a novel, specifically curated dataset of erotic stimuli. Study 1 showed that in the subacute phase, around 2.5 h after intranasal S-ketamine application, SA was attenuated for heterosexual stimuli in female participants and to a lesser degree for lesbian stimuli in male participants. Moreover, aversion to gay stimuli was attenuated for both sexes. Conversely, in Study 2, around 5.5 h after intravenous racemic ketamine application, men exhibited reduced reported SA for heterosexual stimuli, while women demonstrated increased aversion to gay stimuli. In addition, Study 2 identified a ketamine-related reduction in calcarine gyrus activation in men relative to women, irrespective of stimulus orientation. This effect was also evident in resting activity approximately 45 min, but not 4 h after ketamine administration.

Ketamine as a sexual drug

Our finding that ketamine partially reduced ratings of stimuli rated as sexually arousing under placebo 2.5 h after administration is consistent with survey data. 8 While the subacute reduction in SA was mainly observed for heterosexual stimuli in women and to a lesser extent for lesbian stimuli in men, in the late phase (i.e., 5.5 h after administration), we observed reduced SA to heterosexual stimuli only in men. Apart from differences in study design, such as administering S- versus racemic ketamine or using a visual analog scale versus a Likert scale, this pattern could have two causes: On the one hand, the effects of ketamine on SA may not monotonically cease over time. On the other hand, the groups in both studies differed qualitatively in their responses to the placebo. Within-gender differences in preferences for pornographic material in predominantly heterosexual individuals have also been reported across previous studies.5962 It is therefore conceivable that group differences play a role. However, in both studies, ketamine reduced the average responses to stimuli that were sexually arousing under placebo, in men and women.

Besides facilitating intercourse in men that have sex with men (e.g., improving passive anal intercourse 9 —potentially also through ketamine’s analgesic effects, increasing confidence/reducing inhibition 3 ), there might be further attractive properties of ketamine that do not directly increase SA: In a similar vein to ketamine, survey data reveals that 3,4-methylendioxymethamphetamine (MDMA8,63) is also commonly used to enhance sexual pleasure but, at least in men, impairs sexual activity. 64 Based on its ability to enhance closeness, intimacy, and sensual perception, 65 it has been hypothesized that MDMA mimics the post-orgasmic state through increased prolactin levels. 66 Since ketamine also elevates serum prolactin levels 67 and promotes social touch-seeking behavior, 68 similar mechanisms might underlie the consumption of both substances in sexual contexts. However, consuming ketamine in the context of chemsex differs substantially from participating in a clinical study. Thus, targeted investigations are needed to generalize our results beyond the clinical study context.

In addition to attenuating sexually arousing responses, ketamine also reduced aversive responses approximately 2.5 h post-administration. Consistent with prior research, these reductions were most notable for stimuli depicting gay intercourse. 33 The diminished SA and aversion are unlikely to be the result of a reduction in GA, as this was adjusted for in Study 1, and we actually observed an increase in GA to gay stimuli post-ketamine only in men (see Supplemental File for unadjusted models). In addition to being the result of a generally attenuated sexual experience, the reduced sexual aversion could be interpreted in the light of increased openness induced by ketamine. 69 However, this argument should be followed with caution: While increased openness (to experiences) may be an additional facilitating factor among men who have sex with men, it should not be interpreted as increasing the willingness to engage in fundamentally aversive sexual practices.

In Study 2, 5.5 h post-administration of racemic ketamine, and contrary to Study 1, male participants did not report reduced SA to lesbian stimuli but to heterosexual ones. Interestingly, at this time, women rated gay stimuli as more aversive after ketamine than after placebo. Of note, the absence of reduced aversion would not contradict the potential facilitating use of ketamine in the chemsex scene, where acute and subacute effects are of primary interest. While these findings again highlight sex-specific effects, they also indicate that ketamine can increase aversive responses. Supporting this, a study in mice demonstrated that ketamine-induced taste aversion, potentially exacerbating existing frustration. 70 In addition, ketamine was shown to enhance resilience to chronic stress in male but not female mice. 71 The increased aversion observed in female participants during the late, but not subacute, effects of ketamine may reflect an accumulation of negative emotions over time, such as stress from study procedures or fatigue-induced frustration, potentially explaining this differential finding.

Ketamine as a visual drug

The reduced activation for stimuli of all orientations, along with diminished resting activity in the calcarine gyrus observed in men compared to women, indicates that ketamine’s effects might be primarily driven by participant sex, with only a secondary influence of stimulus content. The calcarine gyrus forms part of the primary visual cortex, but has also been linked to attention and reward processing.72,73 This might explain, on the one hand, the interaction effect of participant sex by stimulus orientation—suggesting sex and stimulus-dependent attention and reward—and, on the other hand, the effect of ketamine across stimulus orientations.

Our findings align with prior studies in healthy male individuals that reported reduced activation in primary visual regions under ketamine during smooth pursuit eye movements and visual oddball tasks.14,15 Similarly, earlier research demonstrated reduced blood flow in primary visual regions at rest under ketamine in patients with schizophrenia. 16 The visual components of ketamine’s effects have been consistently reported across various modalities, though often without accounting for participant sex (see Schwertner et al., 74 Frohlich et al. 75 for reviews). These findings related to the visual cortex may reflect ketamine’s psychotomimetic effects, 13 which is consistent with the more pronounced psychosis-like side effects observed in men. 29 The observation that ketamine influenced resting activity at 45 min but not at 4 h post-administration, while a task-related effect was still evident after 5.5 h, could be attributed to the differing psychotomimetic properties of R-ketamine (present in the racemic mixture) compared to S-ketamine. 76 Alternatively, the varying time scales of intrinsic (resting-state) versus stimulus-related (task) activity might explain these differences, but further investigation is warranted.

Moderators of ketamine’s effects on sexual arousal

While our findings corroborate the evidence from survey data on ketamine’s dampening effect on sexual experiences, 8 it should be noted that our study only reflects a small part of this complex relationship. The effects of ketamine on SA depend on several influential factors, including the sex of the participants, the sexual orientation of the stimuli, and the time between drug administration and stimulus exposure. Furthermore, since sexual orientation and gender identity influence SA,24,33,57 they could also modulate the effects of ketamine on sexual experiences. SA also extends far beyond the reaction to visual stimuli, and sexual experiences comprise more than arousal. Although we found no evidence of prohedonic effects of ketamine on subjective SA, such effects may be observed in patients with depression, for whom sexual dysfunction is a common symptom. 77 Thus, targeted investigations are required to test whether ketamine also temporarily dampens SA in patients with depression or if a prohedonic effect prevails. Future studies could also examine the potential moderating effects of sexual orientation or gender identity on ketamine’s impact on SA. In addition, the temporal trajectory of the effects requires further investigation, as we only examined subacute and late stimulus exposure.

Limitations

Although our novel stimulus material was carefully selected with the aim of maximizing inclusivity, no validation or reliability data is currently available. The sample size considerations for both studies did not include sex as a primary variable of interest. This resulted in potentially underpowered subgroups of male and female participants and an unequal sex distribution in Study 2. Thus, our results need to be replicated in a larger, sex-balanced sample. The direct comparability of the two studies is constrained by differences in drug administration protocols and necessary adaptations to the fMRI version of the SA task. In addition, due to logistical factors and task design limitations, Study 1 was adjusted for GA, whereas Study 2 accounted for participants’ sexual orientation. The use of a simplified four-point Likert scale in Study 2 for stimulus ratings may also have influenced responses compared to the visual analog scale employed in Study 1.

Conclusion

Our findings of reduced subjective SA and aversion under subacute ketamine in both men and women support survey data on its use in the chemsex scene. Although ketamine partially diminishes the sexual experience, it is unclear whether the reduced sexual aversion plays a facilitating role in the context of chemsex. In the late phase, the sex-specific effects of ketamine became more pronounced, with men reporting reduced SA, but women actually showing increased sexual aversion. We also observed sex-specific effects on calcarine gyrus activation under ketamine, with relative increases in women and relative decreases in men. These differential findings may be related to previous reports of ketamine-induced increased stress resilience, but also stronger psychotomimetic effects in men. While our work demonstrates sex-specific behavioral and neural effects of ketamine, future studies need to continue resolving the sex bias in ketamine research.

Supplemental Material

sj-docx-1-tpp-10.1177_20451253251406059 – Supplemental material for Sex, drugs, and arousal—two randomized trials on the effects of ketamine on sexual arousal and calcarine gyrus activity

Supplemental material, sj-docx-1-tpp-10.1177_20451253251406059 for Sex, drugs, and arousal—two randomized trials on the effects of ketamine on sexual arousal and calcarine gyrus activity by Manfred Klöbl, Thomas Liebe, Gregor Dörl, Peter Stöhrmann, Clemens Schmidt, Elisa Briem, Christian Milz, Gabriel Schlosser, Maximilian Kathofer, David Gomola, Godber Mathis Godbersen, Julia Sophia Crone, Rupert Lanzenberger and Marie Spies in Therapeutic Advances in Psychopharmacology

sj-pdf-2-tpp-10.1177_20451253251406059 – Supplemental material for Sex, drugs, and arousal—two randomized trials on the effects of ketamine on sexual arousal and calcarine gyrus activity

Supplemental material, sj-pdf-2-tpp-10.1177_20451253251406059 for Sex, drugs, and arousal—two randomized trials on the effects of ketamine on sexual arousal and calcarine gyrus activity by Manfred Klöbl, Thomas Liebe, Gregor Dörl, Peter Stöhrmann, Clemens Schmidt, Elisa Briem, Christian Milz, Gabriel Schlosser, Maximilian Kathofer, David Gomola, Godber Mathis Godbersen, Julia Sophia Crone, Rupert Lanzenberger and Marie Spies in Therapeutic Advances in Psychopharmacology

Acknowledgments

Our special thanks go to the anonymous colleagues who contributed significantly to the creation of the stimulus dataset. We thank the graduated team members and the diploma students of the Neuroimaging Lab (NIL, headed by R. Lanzenberger), as well as the clinical colleagues from the Department of Psychiatry and Psychotherapy for clinical and/or administrative support, especially Thomas Vanicek, Richard Frey, and Siegfried Kasper. We further want to thank Murray Bruce Reed for his support during the MR sequence optimization.

Footnotes

Supplemental material: Supplemental material for this article is available online.

Contributor Information

Manfred Klöbl, Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria; Comprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna, Vienna, Austria.

Thomas Liebe, Department of Psychiatry and Psychotherapy, University of Jena, Jena, Germany.

Gregor Dörl, Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria; Comprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna, Vienna, Austria.

Peter Stöhrmann, Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria; Comprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna, Vienna, Austria.

Clemens Schmidt, Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria; Comprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna, Vienna, Austria.

Elisa Briem, Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria; Comprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna, Vienna, Austria.

Christian Milz, Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria; Comprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna, Vienna, Austria.

Gabriel Schlosser, Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria; Comprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna, Vienna, Austria.

Maximilian Kathofer, Vienna Cognitive Science Hub, University of Vienna, Vienna, Austria.

David Gomola, Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria; Comprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna, Vienna, Austria.

Godber Mathis Godbersen, Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria; Comprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna, Vienna, Austria.

Julia Sophia Crone, Vienna Cognitive Science Hub, University of Vienna, Vienna, Austria.

Rupert Lanzenberger, Department of Psychiatry and Psychotherapy, Medical University of Vienna, Waehringer Guertel 18-20, Vienna 1090, Austria; Comprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna, Vienna, Austria.

Marie Spies, Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria; Comprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna, Vienna, Austria.

Declarations

Ethics approval and consent to participate: Both studies were approved by the ethics committee of the Medical University of Vienna (ethics numbers 2014/2021 and 1572/2021). All procedures were performed in accordance with the Declaration of Helsinki and the good scientific practice guidelines of the Medical University of Vienna. Written informed consent was obtained from all participants.

Consent for publication: Not applicable.

Author contributions: Manfred Klöbl: Data curation; Formal analysis; Investigation; Methodology; Software; Visualization; Writing – original draft; Writing – review & editing.

Thomas Liebe: Conceptualization; Funding acquisition; Investigation; Project administration; Writing – review & editing.

Gregor Dörl: Data curation; Investigation; Writing – review & editing.

Peter Stöhrmann: Data curation; Investigation; Writing – review & editing.

Clemens Schmidt: Investigation; Writing – review & editing.

Elisa Briem: Investigation; Writing – review & editing.

Christian Milz: Investigation; Writing – review & editing.

Gabriel Schlosser: Investigation; Writing – review & editing.

Maximilian Kathofer: Project administration; Writing – review & editing.

David Gomola: Project administration; Writing – review & editing.

Godber Mathis Godbersen: Investigation; Supervision; Writing – review & editing.

Julia Sophia Crone: Conceptualization; Funding acquisition; Project administration; Supervision; Writing – review & editing.

Rupert Lanzenberger: Conceptualization; Funding acquisition; Project administration; Resources; Supervision; Writing – review & editing.

Marie Spies: Conceptualization; Funding acquisition; Investigation; Project administration; Supervision; Writing – review & editing.

Funding: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research was funded in part as an Interdisciplinary Research Cluster Project “Unraveling the aesthetic mind in anhedonia: Insights from pharmacological imaging of the human brain” between the Medical University of Vienna and the University of Vienna [PIs: Rupert Lanzenberger, Julia Sophia Crone]. The personnel costs for Thomas Liebe were covered by the German Research Foundation (DFG; project numbers: 449879371) [PI: Thomas Liebe]. Material costs were covered by the Department of Psychiatry and Psychotherapy (research cost center number 80310110). This research was funded in whole or in part by the Austrian Science Fund (FWF) [grant DOI: 10.55776/KLI1006, PI: Rupert Lanzenberger] and the WWTF Vienna Science and Technology Fund [grant DOI: 10.55776/PAT5436523, Co-PI: Rupert Lanzenberger]. Further funding for this research was provided by the “Medizinisch-Wissenschaftlicher Fonds des Bürgermeisters Bundeshauptstadt Wien” (project number 24101) [PI: Marie Spies]. This research was further supported by the grant “Interdisciplinary translational brain research cluster (ITHC) with highfield MR” from the Federal Ministry of Science, Research and Economy (BMWFW), Austria. Gregor Dörl and Christian Milz are recipients of a DOC Fellowship of the Austrian Academy of Sciences at the Department of Psychiatry and Psychotherapy, Medical University of Vienna. Elisa Briem and Gabriel Schlosser are supported by the MDPhD Excellence Program of the Medical University of Vienna. For open access purposes, the author has applied a CC BY public copyright license to any author-accepted manuscript version arising from this submission. The funding sources had no further role in study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication.

Rupert Lanzenberger received investigator-initiated research funding from Siemens Healthcare regarding clinical research using PET/MR and travel grants and/or conference speaker honoraria from Janssen-Cilag Pharma GmbH in 2023, and Bruker BioSpin, Shire, AstraZeneca, Lundbeck A/S, Dr. Willmar Schwabe GmbH, Orphan Pharmaceuticals AG, Janssen-Cilag Pharma GmbH, Heel and Roche Austria GmbH., and Janssen-Cilag Pharma GmbH in the years before 2020. He has been a shareholder of the start-up company BM Health GmbH, Austria, since 2019. M. Spies has received travel grants from AOP Orphan Pharmaceuticals, Janssen, and Austroplant, speaker honoraria from Janssen and Austroplant, and workshop participation from Eli Lilly. Clemens Schmidt has received a travel grant from Eli Lilly to attend a scientific exchange meeting. The remaining authors have nothing to disclose.

Availability of data and materials: The imaging data cannot be shared due to legal and administrative restrictions. The novel stimulus dataset compiled for the studies presented here will be shared upon request to the corresponding author.

References

  • 1. Nowacka A, Borczyk M. Ketamine applications beyond anesthesia - a literature review. Eur J Pharmacol 2019; 860: 172547. [DOI] [PubMed] [Google Scholar]
  • 2. Wang H, Jonas KJ, Guadamuz TE. Chemsex and chemsex associated substance use among men who have sex with men in Asia: a systematic review and meta-analysis. Drug Alcohol Depend 2023; 243: 109741. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3. Maxwell S, Shahmanesh M, Gafos M. Chemsex behaviours among men who have sex with men: a systematic review of the literature. Int J Drug Policy 2019; 63: 74–89. [DOI] [PubMed] [Google Scholar]
  • 4. Bohn A, Sander D, Köhler T, et al. Chemsex and mental health of men who have sex with men in Germany. Front Psychiatry 2020; 11: 542301. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5. Chakraborty K, Neogi R, Basu D. Club drugs: review of the “rave” with a note of concern for the Indian scenario. Indian J Med Res 2011; 133: 594–604. [PMC free article] [PubMed] [Google Scholar]
  • 6. Smith KM, Larive LL, Romanelli F. Club drugs: methylenedioxymethamphetamine, flunitrazepam, ketamine hydrochloride, and gamma-hydroxybutyrate. Am J Health Syst Pharm 2002; 59: 1067–1076. [DOI] [PubMed] [Google Scholar]
  • 7. Gahlinger PM. Club drugs: MDMA, gamma-hydroxybutyrate (GHB), Rohypnol, and ketamine. Am Fam Physician 2004; 69: 2619–2626. [PubMed] [Google Scholar]
  • 8. Bellomi F, Manenti L, Gheda L, et al. Prevalence and characteristics of Chemsex: a cross-sectional observational study. Eur Addict Res 2024; 30: 43–51. [DOI] [PubMed] [Google Scholar]
  • 9. Bourne A, Reid D, Hickson F, et al. The Chemsex study: drug use in sexual settings among gay and bisexual men in Lambeth, Southwark and Lewisham. Technical Report. London, 2014. [Google Scholar]
  • 10. Zacharias N, Musso F, Müller F, et al. Ketamine effects on default mode network activity and vigilance: a randomized, placebo-controlled crossover simultaneous fMRI/EEG study. Hum Brain Mapp 2020; 41: 107–119. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11. Mueller F, Musso F, London M, et al. Pharmacological fMRI: effects of subanesthetic ketamine on resting-state functional connectivity in the default mode network, salience network, dorsal attention network and executive control network. Neuroimage Clin 2018; 19: 745–757. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12. Liebe T, Danyeli LV, Sen ZD, et al. Subanesthetic ketamine suppresses locus coeruleus-mediated alertness effects: a 7T fMRI study. Int J Neuropsychopharmacol 2024; 27(6): pyae022. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13. Spies M, Klöbl M, Höflich A, et al. Association between dynamic resting-state functional connectivity and ketamine plasma levels in visual processing networks. Sci Rep 2019; 9: 11484. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14. Steffens M, Becker B, Neumann C, et al. Effects of ketamine on brain function during smooth pursuit eye movements. Hum Brain Mapp 2016; 37: 4047–4060. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15. Musso F, Brinkmeyer J, Ecker D, et al. Ketamine effects on brain function–-simultaneous fMRI/EEG during a visual oddball task. Neuroimage 2011; 58(2): 508–525. [DOI] [PubMed] [Google Scholar]
  • 16. Lahti AC, Holcomb HH, Medoff DR, et al. Ketamine activates psychosis and alters limbic blood flow in schizophrenia. Neuroreport 1995; 6: 869–872. [DOI] [PubMed] [Google Scholar]
  • 17. De Moraes CG. Anatomy of the visual pathways. J Glaucoma 2013; 22(Suppl. 5): S2–S7. [DOI] [PubMed] [Google Scholar]
  • 18. Tootell RB, Hadjikhani N, Hall EK, et al. The retinotopy of visual spatial attention. Neuron 1998; 21: 1409–1422. [DOI] [PubMed] [Google Scholar]
  • 19. Petit L, Zago L, Vigneau M, et al. Functional asymmetries revealed in visually guided saccades: an FMRI study. J Neurophysiol 2009; 102: 2994–3003. [DOI] [PubMed] [Google Scholar]
  • 20. Klein I, Paradis AL, Poline JB, et al. Transient activity in the human calcarine cortex during visual–mental imagery: an event-related fMRI study. J Cogn Neurosci 2000: 12(Suppl. 2): 15–23. [DOI] [PubMed] [Google Scholar]
  • 21. Nogo D, Jasrai AK, Kim H, et al. The effect of ketamine on anhedonia: improvements in dimensions of anticipatory, consummatory, and motivation–related reward deficits. Psychopharmacology (Berl) 2022; 239(7): 2011–2039. [DOI] [PubMed] [Google Scholar]
  • 22. Gałuszko–Wȩgielnik M, Wiglusz MS, Słupski J, et al. Efficacy of ketamine in bipolar depression: focus on anhedonia. Psychiatr Danub 2019; 31: 554–560. [PubMed] [Google Scholar]
  • 23. De Luca MT, Meringolo M, Spagnolo PA, et al. The role of setting for ketamine abuse: clinical and preclinical evidence. Rev Neurosci 2012; 23: 769–780. [DOI] [PubMed] [Google Scholar]
  • 24. Klöbl M, Reed MB, Handschuh P, et al. Gender dysphoria and sexual euphoria: a Bayesian perspective on the influence of gender-affirming hormone therapy on sexual arousal. Arch Sex Behav 2024; 53: 1859–1871. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25. Chen BK, Luna VM, LaGamma CT, et al. Sex-specific neurobiological actions of prophylactic (R,S)-ketamine, (2R,6R)-hydroxynorketamine, and (2S,6S)-hydroxynorketamine. Neuropsychopharmacology 2020; 45: 1545–1556. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26. Mastrodonato A, Pavlova I, Kee N, et al. Acute (R,S)-ketamine administration induces sex-specific behavioral effects in adolescent but not aged mice. Front Neurosci 2022; 16: 852010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27. Carrier N, Kabbaj M. Sex differences in the antidepressant-like effects of ketamine. Neuropharmacology 2013; 70: 27–34. [DOI] [PubMed] [Google Scholar]
  • 28. Franceschelli A, Sens J, Herchick S, et al. Sex differences in the rapid and the sustained antidepressant-like effects of ketamine in stress-naïve and “depressed” mice exposed to chronic mild stress. Neuroscience 2015; 290: 49–60. [DOI] [PubMed] [Google Scholar]
  • 29. Ponton E, Turecki G, Nagy C. Sex differences in the behavioral, molecular, and structural effects of ketamine treatment in depression. Int J Neuropsychopharmacol 2022; 25: 75–84. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30. Hickson F. Chemsex as edgework: towards a sociological understanding. Sex Health 2018; 15: 102–107. [DOI] [PubMed] [Google Scholar]
  • 31. Giorgetti R, Tagliabracci A, Schifano F, et al. When “Chems” meet sex: a rising phenomenon called “ChemSex.” Curr Neuropharmacol 2017; 15: 762–770. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32. Malandain L, Mosser S, Mouchabac S, et al. Chemical sex (chemsex) in a population of French university students. Dialogues Clin Neurosci 2021; 23: 39–43. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33. Sylva D, Safron A, Rosenthal AM, et al. Neural correlates of sexual arousal in heterosexual and homosexual women and men. Horm Behav 2013; 64: 673–684. [DOI] [PubMed] [Google Scholar]
  • 34. First MB, Spitzer RL, Gibbon M, et al. Structured clinical interview for DSM-IV Axis I disorders SCID-I: clinician version. Washington, D.C.: American Psychiatric Press, 1997. [Google Scholar]
  • 35. First MB, Williams JBW, Karg RS, et al. Structured clinical interview for DSM-5: clinician version. Arlington, VA: American Psychiatric Association, 2015. [Google Scholar]
  • 36. Osório FL, Loureiro SR, Hallak JEC, et al. Clinical validity and intrarater and test–retest reliability of the Structured Clinical Interview for DSM-5 – Clinician Version (SCID-5-CV). Psychiatry Clin Neurosci 2019; 73: 754–760. [DOI] [PubMed] [Google Scholar]
  • 37. Gorgens KA. Structured clinical interview for DSM-IV (SCID-I/SCID-II). In: Kreutzer JS, DeLuca J, Caplan B. (eds) Encyclopedia of Clinical Neuropsychology. New York, NY: Springer New York, 2011, pp. 2410–2417. [Google Scholar]
  • 38. Hopewell S, Chan AW, Collins GS, et al. CONSORT 2025 statement: updated guideline for reporting randomised trials. PLoS Med 2025; 22: e1004587. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39. van ’t Hof SR, Cera N. Specific factors and methodological decisions influencing brain responses to sexual stimuli in women. Neurosci Biobehav Rev 2021; 131: 164–178. [DOI] [PubMed] [Google Scholar]
  • 40. Liebe T, Li M, Colic L, et al. Ketamine influences the locus coeruleus norepinephrine network, with a dependency on norepinephrine transporter genotype - a placebo controlled fMRI study. Neuroimage Clin 2018; 20: 715–723. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41. Birn RM, Molloy EK, Patriat R, et al. The effect of scan length on the reliability of resting-state fMRI connectivity estimates. Neuroimage 2013; 83: 550–558. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42. Wang J, Ren Y, Hu X, et al. Test-retest reliability of functional connectivity networks during naturalistic fMRI paradigms. Hum Brain Mapp 2017; 38: 2226–2241. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43. Shin W, Koenig KA, Lowe MJ. A comprehensive investigation of physiologic noise modeling in resting state fMRI; time shifted cardiac noise in EPI and its removal without external physiologic signal measures. Neuroimage 2022; 254: 119136. [DOI] [PubMed] [Google Scholar]
  • 44. Beall EB, Lowe MJ. SimPACE: generating simulated motion corrupted BOLD data with synthetic-navigated acquisition for the development and evaluation of SLOMOCO: a new, highly effective slicewise motion correction. Neuroimage 2014; 101: 21–34. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45. Patel AX, Kundu P, Rubinov M, et al. A wavelet method for modeling and despiking motion artifacts from resting-state fMRI time series. Neuroimage 2014; 95: 287–304. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46. Andersson JL, Skare S, Ashburner J. How to correct susceptibility distortions in spin-echo echo-planar images: application to diffusion tensor imaging. Neuroimage 2003; 20: 870–888. [DOI] [PubMed] [Google Scholar]
  • 47. Mueller K, Lepsien J, Möller HE, et al. Commentary: cluster failure: why fMRI inferences for spatial extent have inflated false-positive rates. Front Hum Neurosci 2017; 11: 345. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48. Behzadi Y, Restom K, Liau J, et al. A component based noise correction method (CompCor) for BOLD and perfusion based fMRI. Neuroimage 2007; 37: 90–101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49. Jo HJ, Gotts SJ, Reynolds RC, et al. Effective preprocessing procedures virtually eliminate distance-dependent motion artifacts in resting state FMRI. J Appl Math 2013; 2013: 935154. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50. Jia XZ, Sun JW, Ji GJ, et al. Percent amplitude of fluctuation: a simple measure for resting-state fMRI signal at single voxel level. PLoS One 2020; 15: e0227021. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51. Zang Y, Jiang T, Lu Y, et al. Regional homogeneity approach to fMRI data analysis. Neuroimage 2004; 22: 394–400. [DOI] [PubMed] [Google Scholar]
  • 52. Rue H, Martino S, Chopin N. Approximate Bayesian inference for latent Gaussian models by using integrated nested Laplace approximations. J R Stat Soc B 2009; 71: 319–392. [Google Scholar]
  • 53. Gelman A, Hill J, Yajima M. Why we (usually) don’t have to worry about multiple comparisons. J Res Educ Eff 2012; 5: 189–211. [Google Scholar]
  • 54. Klein F. Are you sure you’re heterosexual? or homosexual? or even bisexual? J Bisexuality 2014; 14: 341–346. [Google Scholar]
  • 55. Cramer RJ, Chevalier C, Gemberling TM, et al. A confirmatory factor analytic evaluation of the Klein sexual orientation grid. Psychol Sex Orientation Gender Diversity 2015; 2: 123–129. [Google Scholar]
  • 56. Olszowy W, Aston J, Rua C, et al. Accurate autocorrelation modeling substantially improves fMRI reliability. Nat Commun 2019; 10: 1220. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57. Safron A, Sylva D, Klimaj V, et al. Neural correlates of sexual orientation in heterosexual, bisexual, and homosexual men. Sci Rep 2017; 7: 41314. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58. Guillaume B, Hua X, Thompson PM, et al. Fast and accurate modelling of longitudinal and repeated measures neuroimaging data. Neuroimage 2014; 94: 287–302. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59. Kohut T, Fernandez K, Fisher WA, et al. What types of pornographic content are people using? a mixed-method analysis that highlights differences by gender and relationship context of use. SCM Studies Commun Media 2024; 13: 465–504. [Google Scholar]
  • 60. Hald GM. Gender differences in pornography consumption among young heterosexual danish adults. Arch Sex Behav 2006; 35: 577–585. [DOI] [PubMed] [Google Scholar]
  • 61. Hald GM, Štulhofer A. What types of pornography do people use and do they cluster? assessing types and categories of pornography consumption in a large-scale online sample. J Sex Res 2016; 53: 849–859. [DOI] [PubMed] [Google Scholar]
  • 62. Ballester-Arnal R, García-Barba M, Castro-Calvo J, et al. Pornography consumption in people of different age groups: an analysis based on gender, contents, and consequences. Sex Res Social Policy 2023; 20: 766–779. [Google Scholar]
  • 63. Evers YJ, Van Liere G, Hoebe C, et al. Chemsex among men who have sex with men living outside major cities and associations with sexually transmitted infections: a cross-sectional study in the Netherlands. PLoS One 2019; 14: e0216732. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64. Buffum J, Moser C. MDMA and human sexual function. J Psychoactive Drugs 1986; 18: 355–359. [DOI] [PubMed] [Google Scholar]
  • 65. Solowij N, Hall W, Lee N. Recreational MDMA use in Sydney: a profile of ‘Ecstacy’ users and their experiences with the drug. Br J Addict 1992; 87: 1161–1172. [DOI] [PubMed] [Google Scholar]
  • 66. Passie T, Hartmann U, Schneider U, et al. Ecstasy (MDMA) mimics the post-orgasmic state: impairment of sexual drive and function during acute MDMA-effects may be due to increased prolactin secretion. Med Hypotheses 2005; 64: 899–903. [DOI] [PubMed] [Google Scholar]
  • 67. Hergovich N, Singer E, Agneter E, et al. Comparison of the effects of ketamine and memantine on prolactin and cortisol release in men. a randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology 2001; 24: 590–593. [DOI] [PubMed] [Google Scholar]
  • 68. Kaldewaij R, Salamone PC, Enmalm A, et al. Ketamine reduces the neural distinction between self- and other-produced affective touch: a randomized double-blind placebo-controlled study. Neuropsychopharmacology 2024; 49: 1767–1774. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69. Breeksema JJ, Niemeijer A, Kuin B, et al. Phenomenology and therapeutic potential of patient experiences during oral esketamine treatment for treatment-resistant depression: an interpretative phenomenological study. Psychopharmacology (Berl) 2023; 240: 1547–1560. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 70. Agüera ADR, Cándido C, Donaire R, et al. Ketamine retards recovery from reward downshift and supports conditioned taste aversion. Pharmacol Biochem Behav 2023; 233: 173671. [DOI] [PubMed] [Google Scholar]
  • 71. Okine T, Shepard R, Lemanski E, et al. Sex differences in the sustained effects of ketamine on resilience to chronic stress. Front Behav Neurosci 2020; 14: 581360. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 72. Natale E, Marzi CA, Girelli M, et al. ERP and fMRI correlates of endogenous and exogenous focusing of visual-spatial attention. Eur J Neurosci 2006; 23: 2511–2521. [DOI] [PubMed] [Google Scholar]
  • 73. Zhao X, Wu S, Li X, et al. Common neural deficits across reward functions in major depression: a meta-analysis of fMRI studies. Psychol Med 2024; 54: 2794–2806. [DOI] [PubMed] [Google Scholar]
  • 74. Schwertner A, Zortea M, Torres FV, et al. Effects of subanesthetic ketamine administration on visual and auditory event-related potentials (ERP) in humans: a systematic review. Front Behav Neurosci 2018; 12: 70. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 75. Frohlich J, Van Horn JD. Reviewing the ketamine model for schizophrenia. J Psychopharmacol 2014; 28: 287–302. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 76. Beck K, Hindley G, Borgan F, et al. Association of ketamine with psychiatric symptoms and implications for its therapeutic use and for understanding schizophrenia: a systematic review and meta-analysis. JAMA Netw Open 2020; 3: e204693. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 77. Atlantis E, Sullivan T. Bidirectional association between depression and sexual dysfunction: a systematic review and meta-analysis. J Sex Med 2012; 9: 1497–1507. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

sj-docx-1-tpp-10.1177_20451253251406059 – Supplemental material for Sex, drugs, and arousal—two randomized trials on the effects of ketamine on sexual arousal and calcarine gyrus activity

Supplemental material, sj-docx-1-tpp-10.1177_20451253251406059 for Sex, drugs, and arousal—two randomized trials on the effects of ketamine on sexual arousal and calcarine gyrus activity by Manfred Klöbl, Thomas Liebe, Gregor Dörl, Peter Stöhrmann, Clemens Schmidt, Elisa Briem, Christian Milz, Gabriel Schlosser, Maximilian Kathofer, David Gomola, Godber Mathis Godbersen, Julia Sophia Crone, Rupert Lanzenberger and Marie Spies in Therapeutic Advances in Psychopharmacology

sj-pdf-2-tpp-10.1177_20451253251406059 – Supplemental material for Sex, drugs, and arousal—two randomized trials on the effects of ketamine on sexual arousal and calcarine gyrus activity

Supplemental material, sj-pdf-2-tpp-10.1177_20451253251406059 for Sex, drugs, and arousal—two randomized trials on the effects of ketamine on sexual arousal and calcarine gyrus activity by Manfred Klöbl, Thomas Liebe, Gregor Dörl, Peter Stöhrmann, Clemens Schmidt, Elisa Briem, Christian Milz, Gabriel Schlosser, Maximilian Kathofer, David Gomola, Godber Mathis Godbersen, Julia Sophia Crone, Rupert Lanzenberger and Marie Spies in Therapeutic Advances in Psychopharmacology


Articles from Therapeutic Advances in Psychopharmacology are provided here courtesy of SAGE Publications

RESOURCES